How to Build a Finished-Product Release Specification for a Supplement

Before requesting a quotation, translate the marketing concept into a dose, material basis, serving, process route, evidence plan, package, and volume range.

Better procurement decisions come from comparable specifications, verified scope, product-specific evidence, and visible commercial trade-offs.

This article focuses on identity, assay, physical attributes, micro, heavy metals, moisture, disintegration/dissolution and packaging. The objective is to help a brand reach a defensible next decision, not to imply that one formula, parameter, or format is universally correct.

Quick Answer

What the Brand Should Decide First

Turn the decision into a written comparison: required scope, evidence, ownership, cost assumptions, timing, and approval gates. Verify documents at their issuing source and compare suppliers on the same basis.

At minimum, obtain clear answers for:

  • Product identity

  • Active assay

  • Physical attributes

  • Microbiological limits

  • Heavy-metal limits

  • Moisture or water activity

  • Disintegration or dissolution

  • Package and label conformity

The Core Manufacturing Decision

Fix the Product Basis Before the Sales Answer

Strategic objective: Turn QA knowledge into a practical specification framework. In practice, the article and RFQ should lead to a specific dosage-form, evidence, packaging, or commercial decision.

Write mandatory requirements separately from preferences. A supplier can challenge a preferred flavor, unit count, or package; it should not quietly change the target dose or market basis to make the quote easier.

Product identity

What the Brand Should Define and Verify

The term product identity is incomplete without a specification, sampling plan, method, matrix suitability, units, timing, and disposition rules.

Request a sample report for product identity and confirm whether it represents raw material, in-process material, bulk product, or packaged finished product.

Define product identity before quoting so every supplier includes equivalent evidence and laboratory cost.

Active assay

What the Brand Should Define and Verify

The term active assay is incomplete without a specification, sampling plan, method, matrix suitability, units, timing, and disposition rules.

Request a sample report for active assay and confirm whether it represents raw material, in-process material, bulk product, or packaged finished product.

Define active assay before quoting so every supplier includes equivalent evidence and laboratory cost.

Physical attributes

What the Brand Should Define and Verify

Physical attributes is a decision input rather than a promotional label. Define who supplies the information, which document controls it, and what outcome is acceptable.

Ask each candidate to show how physical attributes is documented, verified, priced, and approved within the proposed project.

Resolve physical attributes before final quotation so suppliers do not price different interpretations of the requirement.

Microbiological limits

What the Brand Should Define and Verify

The term microbiological limits is incomplete without a specification, sampling plan, method, matrix suitability, units, timing, and disposition rules.

Request a sample report for microbiological limits and confirm whether it represents raw material, in-process material, bulk product, or packaged finished product.

Define microbiological limits before quoting so every supplier includes equivalent evidence and laboratory cost.

Heavy-metal limits

What the Brand Should Define and Verify

Heavy-metal limits is a decision input rather than a promotional label. Define who supplies the information, which document controls it, and what outcome is acceptable.

Ask each candidate to show how heavy-metal limits is documented, verified, priced, and approved within the proposed project.

Resolve heavy-metal limits before final quotation so suppliers do not price different interpretations of the requirement.

Moisture or water activity

What the Brand Should Define and Verify

Water activity describes available water rather than total moisture. It is product-specific and must be interpreted with texture, microbial risk, chemical stability, and package performance.

The risk behind moisture or water activity can affect chemical potency, physical condition, sensory quality, microbiology, and packaging at different rates.

For moisture or water activity, define intervals, conditions, package, attributes, methods, criteria, and the decision rule for accelerated and real-time data.

Do not set moisture or water activity from a related formula unless comparability of formula, process, and package is documented.

Disintegration or dissolution

What the Brand Should Define and Verify

A useful dissolution target defines water volume, temperature, endpoint, agitation assumptions, foam behavior, residue, and an acceptable time range rather than relying on the phrase 'fast dissolving.'

The endpoint for disintegration or dissolution must reflect consumer use and distinguish breakup, dispersion, dissolution, foam collapse, and visible residue where relevant.

Write the disintegration or dissolution method with water volume, temperature, vessel, agitation, timing start, endpoint, sample size, and acceptance range.

Approve the disintegration or dissolution target only if strength, handling, taste, and package stability remain acceptable.

Package and label conformity

What the Brand Should Define and Verify

The decision on package and label conformity must account for exposure during production, component storage, filling, sealing, distribution, and repeated consumer opening.

For package and label conformity, request component specifications, closure controls, line compatibility, integrity checks, and stability in the proposed commercial pack.

Approve package and label conformity as part of the protection system first and as a branding choice second.

Manufacturing Mechanics

Supplier Qualification and Product Strategy

A manufacturing decision becomes reliable only when the commercial brief, technical specification, quality evidence, and quotation assumptions describe the same product.

Logos, catalogs, and headline prices are screening inputs. They do not replace facility scope, dosage-form capability, batch records, test methods, change control, or an itemized commercial model.

The brand should define what is mandatory, what is preferred, and what remains open to manufacturer recommendation. This prevents suppliers from solving different problems under one RFQ.

Manufacturability includes more than making one batch. The process must tolerate normal raw-material and operating variation while keeping the finished product within specification.

Control and Evidence Plan

What to Review Before Release

The control plan should concentrate on the failure modes created by this formula and format. Relevant controls include:

  • Clear ownership and approval gates

  • Written specifications and revision control

  • Qualified suppliers and traceability

  • Representative testing and quality review

  • Documented deviations, changes and release decisions

The corresponding evidence package may include:

  • Certificate holder, address, scope and validity

  • Master and batch manufacturing records

  • Specifications and test methods

  • Representative COAs and laboratory reports

  • Capacity, contingency and change-control evidence

Representative sampling matters when segregation, settling, fill variation, or unit-to-unit variability is plausible. A convenient grab sample may answer the wrong question.

Commercial Model

Compare the Complete Serving and Launch Commitment

The commercial comparison should include:

  • Development and sample fees

  • Inventory, packaging and test commitments

  • Transparent assumptions and exclusions

  • Lead time by stage

  • Reorder capacity and backup risk

Include the inventory consequences of packaging print runs and ingredient minimums. Materials left behind at the factory still represent brand cash and obsolescence risk.

Supplier Questions

Questions That Expose the Real Capability

  • Does the quotation describe the same specification from every supplier?

  • Which claims are supported and which remain the brand's responsibility?

  • What evidence is reviewed before release?

  • Which cost or MOQ is fixed by a third party?

  • How are changes, delays and nonconforming results communicated?

  • What commercial evidence supports the proposed approach to product identity?

  • What commercial evidence supports the proposed approach to active assay?

  • What commercial evidence supports the proposed approach to physical attributes?

  • Which quotation assumptions can change after sampling?

  • Who approves formula revisions, deviations, packaging changes, laboratory results, and final release?

Red Flags

When to Pause the Project

  • The quotation excludes material items but does not state the exclusions

  • The supplier confirms feasibility before receiving dose, material, serving, market, and package details

  • The answer to product identity is promotional rather than measurable

  • A laboratory sample is described as proof of routine commercial performance

  • The raw-material COA is offered as the finished-product result

  • One shelf life or standard test panel is applied to unrelated formulas

  • Certificate logos are shown without holder, facility address, scope, validity, and verification route

  • MOQ is stated without identifying the process, material, component, tooling, or test driver

How VitaMFG Approaches the Project

Review a Product Specification

The starting point is a controlled brief shared across formulation, production, quality, packaging, and commercial teams.

If the original request creates a conflict among dose, unit count, material behavior, sensory quality, stability, or cost, the alternatives should be presented explicitly. Facility-level quality credentials support supplier qualification; they do not replace product-specific release and stability evidence.

Frequently Asked Questions

Q1: Can this project be quoted accurately without a full brief?

Not reliably. Missing assumptions will either be added by the supplier or priced later, which makes early quotations difficult to compare.

Q2: Does a successful sample prove the product is ready?

No. It supports the concept and sensory direction. Scale-up, representative testing, package performance, and stability still need appropriate evidence.

Q3: What is the most useful first document to send?

Send a one-page project brief with formula basis, amount per serving, dosage form, directions, target market, package, tests, order range, and launch date.

Final Recommendation

Approve the product only after the brief, scale-up plan, release specification, package, stability rationale, and commercial terms describe the same SKU.

With the target dose, market, serving, package, and volume defined, the next step is: Review a Product Specification.

  • U.S. FDA — Dietary Supplement CGMP Compliance Guide

  • Electronic Code of Federal Regulations — 21 CFR Part 111